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B-chronic lymphocytic leukemia (B-CLL) patients have a high prevalence of autoimmune
phenomena, mainly autoimmune hemolytic anemia (AIHA). Immunoregulatory cytokines
play a role in the regulation of both autoimmunity and leukemic B-cell growth. Mitogen-
stimulated direct antiglobulin test (MS-DAT) is a recently described test able to disclose
latent anti-RBC autoimmunity in AIHA. We investigated the prevalence of anti-RBC au-
toimmunity by MS-DAT and the pattern of cytokine production by PHA-stimulated whole
blood cultures from 69 B-CLL patients and 53 controls. Results showed that anti-RBC IgG
values in unstimulated, PHA-, PMA-, and PWM-stimulated cultures were significantly
higher in B-CLL patients compared with controls. In B-CLL, the prevalence of anti-RBC
autoimmunity was 28.9% by MS-DAT, compared with 4.3% by the standard DAT. Produc-
tion of IFN-, IL-2, IL-13, TNF-, sCD23, and sCD30 was significantly increased in all
B-CLL patients compared with controls, whereas there was no difference in IL-4, IL-6,
IL-10, and TGF- production. Multivariate analysis showed that IL-4 was significantly
increased in MS-DAT-positive compared with -negative patients. Patients with autoanti-
body positivity displayed greater IFN- production than negative patients. These data are
in line with the hypothesis that autoimmune phenomena in B-CLL are associated with an
imbalance towards a Th-2-like profile. The elevated prevalence of anti-RBC autoimmunity
found by MS-DAT suggests that an underestimated latent autoimmunity exists in B-CLL.
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INTRODUCTION
B-chronic lymphocytic leukemia (B-CLL) patients
have a high prevalence of autoimmune phenomena due
to polyclonal autoantibodies mainly restricted to blood
cell self-antigens [1]. Autoimmunity has been related to
B-CLL biological properties and cellular origin as well
as to microenvironmental factors. The malignant cell is a
mantle-zone-like CD5+ B cell, which is normally de-
voted to the production of polyreactive natural autoanti-
bodies. These cells are in the G0 phase of the cell cycle,
but express activation membrane molecules such as
CD23, CD27, and CD30 and are able to secrete a variety
of cytokines. The precise role of these environmental
factors is still unclear. Some cytokines, including TNF-,
IL-1, IL-2, IL-4, and IFN- have been proposed as au-
tocrine growth-promoting factors, through prevention of
apoptosis [2–5]. On the contrary, other cytokines may be
responsible for negative autocrine circuits. IL-10 inhibits
the in vitro PMA- and PMA plus anti-Ig-induced prolif-
eration of leukemic B-cells [6] and promotes apoptosis
[7]; IL-6 is an inhibitory factor for TNF--induced B-cell
proliferation [8]. Bone marrow stromal cells from B-CLL
patients produce increased amounts of TGF- [9], which
likely exerts an inhibiting activity on hematopoietic pre-
cursors; however, peripheral B-cells from patients lack
responsiveness to the antiproliferative and pro-apoptotic
effects of TGF-, probably because of decrease or loss of
TGF- receptor expression [10].
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In spite of the growing evidence on the effect of ex-
ogenous cytokines on leukemic cells, there are conflict-
ing reports regarding cytokine production in B-CLL.
PHA-stimulated cultures of T cells from B-CLL patients
show increased production of IL-2, IL-4, IFN-, and
TNF- [11,12]. At variance, intracellular IL-4 and IFN-
are reduced in CD4+ T cells from patients [13]. Produc-
tion of IL-6 is decreased in PMA- and PMA plus IL-2-
stimulated PBMC from patients in advanced disease
stage [14]. On the contrary, serum levels of IL-6 and
IL-10 are elevated and correlate with adverse disease
features and short survival [15].
Autoimmune responses are controlled by complex
regulatory circuits, which also involve immunoregulato-
ry cytokines [16]. Several sources of evidence support
the idea that T-helper (Th)-1-inducing cytokines (IL-2,
IL-12, IFN-) can upregulate T-cell autoimmunity,
whereas cytokines that promote Th-2 differentiation (IL-
4, IL-6, IL-13, IL-10) and downregulate Th-1 responses
(TGF-, IL-4) are invariantly associated with protection
from autoimmune diseases. However, there are several
exceptions to these scenarios, which indicate a prevalent
Th-2 profile in systemic autoimmune diseases [16]. Au-
toimmune hemolytic anemia (AIHA) is the most frequent
autoimmune complication of B-CLL. In AIHA Th-2 (IL-
4, IL-6, IL-13) cytokines are elevated and Th-1 is re-
duced. We recently described a new method for the de-
tection of anti-RBC antibodies in mitogen-stimulated
whole blood cultures, termed mitogen-stimulated direct
antiglobulin test (MS-DAT). The test was suitable for
revealing cytokine modulation of anti-RBC antibody
production and disclosing a latent autoimmunity, since
mitogen stimulation induced antibody production in
AIHA in clinical remission [17].
The aim of this study was to investigate the prevalence
of anti-RBC autoimmunity by MS-DAT and to study
patterns of in vitro cytokine production by PHA-
stimulated whole blood cultures from B-CLL patients.
Th-1 (IL-2, IFN-), Th-2-like (IL-4, IL-6, IL-10, IL-13),
proinflammatory (TNF-), inhibitory (TGF-) cyto-
kines, and soluble activation markers (sCD23, sCD30)
were correlated with anti-RBC autoimmunity, disease
stage, and therapy.
MATERIALS AND METHODS
Patients
Sixty-nine patients with B-CLL (mean age ± SD 68 ±
11 years, range 41–89, 25 female and 44 male) and 53
age- and sex-matched healthy regular blood donors were
studied as controls. B-CLL was diagnosed according to
defined clinical, morphological, and immunological cri-
teria [18]. Patients were staged according to the guide-
lines proposed by Binet et al [19].
Reagents
Phorbol-12-myristate-13-acetate (PMA) and phytohe-
magglutinin (PHA) were from Sigma-Aldrich Chemicals
(St. Louis, MO); pokeweed (PWM) from Gibco Labora-
tories (Grand Island, NY). Commercial monoclonal re-
agents (anti-IgG+C, anti-IgG, anti-C3d, and anti-C3c)
rabbit antihuman IgA and sheep antihuman IgM were
from Ortho (Raritan, NJ), Bioscot (Edinburgh, UK), and
Gamma (Houston, TX) were used for tube-DAT.
DAT and Nonorgan-Specific
Autoantibody Determination
Tube-DAT was performed according to standard tech-
niques using both polyspecific and monospecific sera
[20]. The cassette-DAT (BioVue Ortho) was carried out
with monospecific antiserum only, following the manu-
facturer’s instructions. The presence of rheumatoid factor
(RF), antinuclear (ANA), antimitochondrial (AMA), an-
tismooth muscle (SMA), anticardiolipin (ACA), antithy-
roid peroxidase (TPO), antithyreoglobulin, anti-dsDNA,
and anti-extractable nuclear antigens (ENA), namely,
Sm, nRNP, SSA-Ro, SSB-La, Scl-70, and Jo-1 antibod-
ies were determined by commercially available ELISA
kits according to conventional techniques.
Culture Conditions
Fresh heparinized blood samples were diluted 1:6 with
RPMI 1640 medium (Gibco) and either unstimulated or
stimulated with mitogens and/or cytokines in 24-well
plates and incubated for 48 hr, according to previous
experiments [21–23]. Forty-eight-hour cultures were
stimulated with 2 g/ml PHA, 20 ng/ml PMA, 1%
PWM. After 48-hr culture, RBC were washed four times
with phosphate-buffered saline (PBS), centrifuged at
1,000 rpm for 10 min, resuspended in PBS at 10% con-
centration, and processed for the quantitation of anti-
autologous RBC bound IgG, as detailed below.
Anti-RBC-Bound IgG Quantitation
The quantitation of RBC-bound IgG was evaluated
with a competitive solid-phase enzyme immunoassay, as
previously described [17]. Briefly, 96-well plates were
coated with 50 l of human IgG overnight at 4°C, then
3× washed, and blocked with 200 l of 2% FCS-PBS for
2 hr at room temperature. A standard curve was con-
structed with group 0 CcDee RBC (200 l of 10% sus-
pension in 0.2% FCS-PBS) sensitized with serial dilu-
tions (4,000–37.5 ng/ml) of anti-Rh antibody (Immuno
AG, Vienna, Austria) for 1 hr at 37°C. The cell suspen-
sion was then 3× washed and incubated with peroxidase-
conjugated rabbit antihuman IgG (Dako, Denmark) di-
luted 1:3,000 in 0.2% FCS-PBS at 37°C for 30 min. One
hundred l of this mixture were added to the IgG-coated
plates and incubated at 37°C for 30 min. After 5×
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washes, 50 l of o-phenylenediamin dihydrochloride
was added to each well. The colorimetric reaction was
measured at 450 nm after 15 min with an ELISA spec-
trophotometer. For determination of anti-RBC on autolo-
gous cultured RBC, cultured cell suspensions were
treated as anti-Rh-sensitized CcDee RBC. Briefly, the
cell culture suspension was 3× washed, incubated with
peroxidase-conjugated rabbit antihuman IgG for 30 min,
added to the IgG-coated plates, and further incubated for
30 min. After 5× washes the colorimetric reaction was
evaluated. A log/log plot was constructed with OD val-
ues and anti-Rh antibody concentration of the standard
curve (ng/ml), and autologous anti-RBC-bound IgG
value was calculated referring to this standard curve. To
determine a cutoff for MS-DAT positive values, the
mean of PHA-, PMA-, and PWM-stimulated cultures of
controls was calculated and the positivity for MS-DAT
defined as a value exceeding the mean plus 3 SD of
controls (220 IgG ng/ml).
Cytokine and Soluble Activation
Markers Production
Cytokine production was measured in 48-hr PHA-
stimulated culture supernatants using commercially
available ELISA kits according to the manufacturers’
instructions. IL-2, IL-4, IL-13, IFN-, TGF- were pur-
chased from Amersham Pharmacia Biotech (Bucking-
hamshire, UK) and TNF-, IL-6, IL-10 from Cytimmune
(College Park, MD). sCD23 from Bender Medical Sys-
tems (Vienna, Austria) and sCD30 from Dako A/S (DK-
2600, Glostrup, Denmark).
Statistical Analysis
Univariate analysis was performed by means of un-
paired Student’s test for unequal variances. Multivariate
analysis was performed by means of multiple logistic
regression using the SAS package, v. 7.0 (SAS, Cary,
NC). Comparisons between values at baseline and after
stimulation were performed by two-tailed Student’s t-test
for paired data. Probability values <0.05 were considered
statistically significant.
RESULTS
Clinical and Laboratory Characteristics of
B-CLL Patients
At the time of the study, 24 patients were in Stage A,
21 in B, and 14 in C. Mean disease duration ± SE was 22
± 4.5 months (range 1–219). Stage A and B patients were
either untreated (n 29 and n 4, respectively), treated
with chlorambucil (n 5 and n 13), or fludarabine (n
 0 and n  4); one of the fludarabine-treated patients
also received CEOP chemotherapy. Stage C patients
were treated with chlorambucil alone or associated with
prednisone (n  6), fludarabine (n  7), and CEOP
(n  1); one of the fludarabine-treated patients also re-
ceived cyclophosphamide chemotherapy.
The leukocyte and absolute lymphocyte number of pa-
tients was 18,069 ± 1,936/l and 12,278 ± 1,602/l
(mean ± SE of Stage A patients, respectively), 32,931 ±
6,474/l and 24,697 ± 5,549/l (Stage B patients), and
23,685 ± 7,914/l and 13,281 ± 5,307/l (Stage C pa-
tients). Twelve Stage C patients had anemia (Hb < 10
g/dl) and 21 patients (9 Stage A, 12 Stage B) have mild
anemia (female: Hb 10–11.5 g/dl; male: Hb 10–13 g/dl).
As far as classic hemolytic signs are concerned (reticu-
locyte count greater than 2%, LDH greater than 460 U/l,
and haptoglobin lower than 600 mg/l), only the latter was
considered for B-CLL patients, since LDH could be el-
evated and reticulocytes reduced because of lymphopro-
liferative disease and bone marrow failure, respectively.
Thirteen (three Stage A, five Stage B, and five Stage C)
had anemia (female: Hb <11.5 g/dl; male: Hb <13 g/dl)
with haptoglobin levels below the normal range. Three
Stage C patients suffered from DAT-positive-AIHA and
were being treated with HD-chlorambucil and predni-
sone; 2/3 were still DAT-positive, whereas one became
DAT-negative at the time of the study. The prevalence of
AIHA in our series was therefore 4.3%.
MS-DAT in B-CLL Patients
Figure 1 shows the amount of anti-RBC IgG in un-
stimulated and mitogen-stimulated cultures from B-CLL
patients and controls. Anti-RBC IgG values were signifi-
cantly higher in B-CLL patients compared with controls
in all the experimental conditions tested (P  0.002 for
unstimulated cultures, P 0.0004 for PHA- and PWM-
stimulated cultures, P  0.01 for PMA-stimulated cul-
tures). Mitogen stimulation had no effect in controls,
whereas it significantly increased anti-RBC IgG value in
B-CLL patients (P 0.001 and 0.04 for PHA and PWM,
respectively). MS-DAT was positive in 20 B-CLL pa-
tients (ten in Stage A, four in Stage B, six in Stage C),
corresponding to a prevalence of 28.9%.
To ascertain whether MS-DAT positivity was associ-
ated with other autoimmune markers, determination of
serum autoantibodies was carried out in 42 B-CLL pa-
tients. We found 14 positive patients (33%)—three RF,
three ANF, one SMA, one ACA, two anti-TPO, three
antithyreoglobulin, and one anti-dsDNA; 3/14 were also
MS-DAT-positive.
Multivariate analysis showed no relationship between
MS-DAT positivity and all the clinical and laboratory
parameters considered (age, sex, disease duration, and
therapy; WBC, lymphocyte, RBC, and reticulocyte
counts, Hb, Ht, haptoglobin, LDH, bilirubin levels, and
autoantibody positivity).
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Cytokine Production in Whole Blood Cultures
From B-CLL Patients
As shown in Table I, production of IL-2, IFN-, TNF-
, and IL-13 was significantly increased in B-CLL pa-
tients compared with controls. There was no difference in
IL-4, IL-6, IL-10, and TGF- production. The increased
production of IL-2, IFN-, TNF-, and IL-13 was re-
stricted to Stage A and B patients. Stage C patients dis-
played IL-2, IFN-, TNF-, and IL-13 values signifi-
cantly decreased compared with Stage A patients. To
ascertain whether therapy could have affected cytokine
production, untreated and treated (chlorambucil, predni-
sone, fludarabine, and other) patients were compared.
No difference was found in IFN-, IL-2, IL-10, IL-13,
TNF-, IL-4, IL-6, and TGF- production (data not
shown). At variance, by comparing fludarabine-treated
vs. the other patients, production of all the cytokines
investigated was reduced (on average 50%) in the
former. In particular, IL-2 production was significantly
reduced in the fludarabine-treated group compared with
the other patients (295 ± 209 vs. 1,112 ± 112 pg/ml, mean
± SE of 11 and 58 patients, respectively, P 0.003).
Along with cytokine production, sCD23 and sCD30
levels were investigated in PHA-stimulated culture su-
pernatants (Table I). Both soluble markers were signifi-
cantly increased in B-CLL patients compared with con-
trols. No clear relationship with disease stage was
observed for sCD23, whereas a clear increase in Stage C
was found for sCD30. Considering the relationship
between cytokine production and soluble CD markers,
values of sCD23 were positively correlated with those
of IFN- (r 0.623, P 0.001) and IL-10 (r 0.467,
P  0.001). TA
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Fig. 1. Effect of mitogen stimulation on in vitro autologous
anti-RBC bound IgG values in B-CLL patients and controls.
Autologous anti-RBC bound IgG values were assessed in
48-hr whole blood cultures and expressed as IgG µg/l, mean
± SE of 69 patients (solid bars) and 53 controls (open bars).
Statistically significant comparisons of B-CLL cultures vs.
controls are indicated.
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As far as MS-DAT positivity is concerned, patients
with positive values of anti-RBC IgG displayed in-
creased values of PHA-stimulated IL-4 production com-
pared with MS-DAT-negative patients (Fig. 2, left). Mul-
tivariate analysis and maximum likelihood estimates
showed that IL-4 was significantly increased in MS-
DAT-positive compared with negative patients (P 
0.0017). No difference in the other cytokines, sCD23,
and sCD30 values were found between MS-DAT-
positive and -negative subjects. Patients with autoanti-
body positivity displayed lower IFN- production than
negative patients (Fig. 2, right). No difference in the
other cytokines, sCD23, and sCD30 values were found.
DISCUSSION
The results show that autoimmune phenomena, either
directed against RBC or other autoantigens, are frequent
in B-CLL patients, in line with previous findings [24,25],
but in disagreement with Hamblin et al. [26], who found
high levels of autoantibodies, but no higher than in age-
matched controls. Here we show that the prevalence of
anti-RBC autoimmunity estimated by MS-DAT is even
greater (roughly six times) than that estimated by the
standard DAT. This finding suggests that mitogen stimu-
lation is able to disclose a latent autoimmunity in B-CLL,
as shown in AIHA [17].
Since immunoregulatory cytokines are involved in the
pathogenesis of autoimmunity and AIHA, we asked
whether a different cytokine pattern could be found in
B-CLL patients with or without anti-RBC autoimmunity.
To this end, in the same mitogen-stimulated whole blood
cultures in which MS-DAT was determined, we investi-
gated cytokine secretion. First, the whole B-CLL popu-
lation was considered. An increased production of IL-2,
IFN-, TNF-, and IL-13 was found, whereas secretion
of IL-4, IL-6, IL-10, and TGF- was comparable to con-
trols. Our findings are in agreement with those of Reyes
et al. [11], who showed increased production of IL-2,
IFN-, and TNF- by T-cells. IFN- was reported to
inhibit apoptosis [4] and TNF- and IL-2 to act as auto-
crine growth-promoting factors of leukemic B-cells
[2,5]. Therefore, the increased production of these cyto-
kines could contribute to the accumulation of leukemic
B-cells. IL-13, a Th-2-like cytokine, is a growth-
promoting factor for B-normal lymphocytes stimulated
with anti-IgM antibody and induces the expression of
CD23 [27]. Even if its effects on the leukemic B-cells
need to be studied, the increased production of this Th-
2-like cytokine could contribute to the expansion of leu-
kemic B-cells. In addition, it has been reported that IL-13
induces IFN- production by NK cells [27], which in
turn could exert further antiapoptotic effects on leukemic
B-lymphocytes.
Considering cytokine production in B-CLL patients
with positivity for MS-DAT or serological autoantibod-
ies, we found increased IL-4 in the former and reduced
IFN- production in the latter. These data are in line with
the hypothesis that autoimmune phenomena in B-CLL
are associated with an imbalance towards a Th-2-like
profile. Increased IL-4 and reduced IFN- has been
documented in the paradigmatic autoimmune disease
SLE, consistent with the prevalent humoral autoimmu-
nity observed in this disease [28]. Furthermore, increased
Fig. 2. IL-4 and IFN- production in B-CLL patients with MS-DAT or autoantibody positivity. Cytokine production was
assessed in PHA-stimulated 48-hr whole blood cultures from B-CLL patients. Values are expressed as pg/ml, mean ± SE
of 69 patients. Statistically significant comparisons are shown.
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IL-4 was found in AIHA, both in vivo [29,30] and in
vitro [17], in line with the immunopathogenic mecha-
nism involved in RBC destruction, i.e., complement-
mediated autoantibody lytic activity and antibody-
dependent cellular cytotoxicity.
As far as the activation markers investigated are con-
cerned, we found increased sCD23 production in mito-
gen-stimulated cultures of B-CLL patients, in line with
several reports in the literature [31–34]. However, con-
trary to what was found in sera, in culture supernatants
there was no relationship with disease stage. Likewise,
sCD30 was increased in mitogen-stimulated cultures of
B-CLL patients compared with controls, particularly in
advanced stage patients. Our results are in line with pre-
vious findings indicating that this TNF-superfamily li-
gand is involved in B-CLL pathogenesis, both in main-
taining neoplastic growth and regulating the apoptotic
phenomena [35–37]. Notwithstanding several reports on
the role of CD23 and CD30 in autoimmunity [38–42],
our results showed no difference in sCD23 and sCD30
between B-CLL patients with or without autoimmune
features.
Our results demonstrate a high prevalence of anti-RBC
autoimmunity by MS-DAT in B-CLL. We do not know
why the cells can be driven to make RBC autoantibodies
in vitro, but not in vivo. However, the ability of mitogen
stimulation to induce antibody production suggests that
an underestimated latent autoimmunity exists in B-CLL.
The clinical and prognostic significance of these data is
still uncertain. There was no relationship between MS-
DAT positivity and disease stage, hemolytic parameters,
or positivity for other serological markers of autoimmu-
nity. In any case, it should be noted that, 3 months after
the end of the study, one of the MS-DAT-positive pa-
tients developed DAT-negative hemolytic anemia which
recovered after steroid administration. Furthermore, an-
other MS-DAT-positive patient developed autoimmune
thrombocytopenia and DAT-negative hemolytic anemia
and died of rapidly progressive disease with infective
complications.
CONCLUSION
The high prevalence of anti-RBC autoimmunity by
MS-DAT suggests the existence of an underestimated
latent autoimmunity in B-CLL. MS-DAT positivity
could have a predictive value on the development of
AIHA or autoimmune complications; a longer clinical
follow-up and study of a larger series of patients could
confirm this capability. The imbalance towards a Th-2-
like cytokine profile in B-CLL with autoimmune features
suggests hints for the future development of anti-
cytokine treatment in B-CLL.
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